8-K: ImmunityBio ANKTIVA Gets EU Conditional Marketing Nod for Bladder Cancer

ImmunityBio's ANKTIVA, combined with BCG, received a conditional marketing authorization recommendation from the European Medicines Agency for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ.

Summary

• ImmunityBio received a conditional marketing authorization recommendation from the European Medicines Agency (EMA) for ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Gurin (BCG).
• The recommendation is for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors, in adults.
• This marks the first immunotherapy for NMIBC CIS to receive a positive recommendation for marketing authorization in Europe.
• For patients whose disease does not respond to BCG, the primary option is currently surgical removal of the bladder (radical cystectomy).
• The decision was based on a single-arm clinical trial of 100 adults, showing a 71% complete response rate, with responses lasting approximately 27 months on average and up to 54+ months.
• Complete response rates were 66% at 12 months and 42% at 24 months.
• ImmunityBio will submit long-term safety and efficacy post-marketing results to the EMA as part of the conditional authorization.
• The EMA's opinion will now be forwarded to the European Commission for final EU-wide marketing authorization.

Sentiment

Score: 8

Explanation: The conditional marketing authorization recommendation from the EMA is a major positive regulatory milestone, addressing a significant unmet medical need with strong clinical data. The 'conditional' nature and the need for post-marketing data, along with strategic assessment for European launch, introduce minor caveats, but overall, it's a very strong positive development for the company and patients.

Positives

• Conditional marketing authorization recommendation from the European Medicines Agency (EMA) for ANKTIVA plus BCG.
• ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) to receive a positive recommendation in Europe.
• Addresses a significant unmet medical need for patients with BCG-unresponsive NMIBC, where the primary alternative is surgical bladder removal.
• Clinical trial results showed a 71% complete response rate, with responses lasting approximately 27 months on average and up to 54+ months.
• Complete response rates of responders were 66% at 12 months and 42% at 24 months.
• Builds on existing approvals in the U.S. and United Kingdom.
• Europe has approximately six major BCG substrains approved, potentially facilitating broader use of ANKTIVA.

Negatives

• The authorization is "conditional," requiring ImmunityBio to submit long-term safety and efficacy post-marketing results to the EMA.
• The EMA's decision was based on a single-arm clinical trial, which inherently carries higher risk compared to randomized controlled trials.
• The company is "thoughtfully assessing" its approach to launching in Europe due to the U.S. Most-Favored-Nation Prescription Drug Pricing policy, which could imply slower or more complex market entry.

Risks

• Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal.
• If patients with CIS do not have a complete response after a second induction course of ANKTIVA with BCG, reconsideration of cystectomy is advised.
• General risks associated with forward-looking statements, including uncertainties regarding clinical trial results, regulatory acceptance, funding, product availability, manufacturing disruptions, commercialization success, and intellectual property protection.

Future Outlook

ImmunityBio aims to finalize plans to bring ANKTIVA to qualified EU patients and is developing a recombinant BCG candidate to address ongoing BCG shortages in the U.S. and ensure patient access. The company expects the EMA's opinion to be forwarded to the European Commission for final EU-wide marketing authorization.

Management Comments

• "ANKTIVA represents an important evolution in the treatment of NMIBC CIS, strengthening the immune response and improving the durability of BCG." Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.
• "Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible, to ensure avoidance of a radical cystectomy." Dr. Patrick Soon-Shiong.
• "We are pleased that the EMA issued this positive recommendation based on our single-arm trial and through a regulatory process that allows earlier access to ANKTIVA, when as stated in the EMA announcement, the benefit of a medicines immediate availability to patients outweighs the inherent risks." Dr. Patrick Soon-Shiong.
• "We are looking forward to finalizing plans to bring our innovative treatment to qualified EU patients." Richard Adcock, President and CEO of ImmunityBio.
• "With the United States new Most-Favored-Nation Prescription Drug Pricing policy now in effect, we are thoughtfully assessing our approach to launching in Europe to ensure broad, equitable, and sustainable access." Richard Adcock.
• "Six BCG strains are available in Europe for use in combination with ANKTIVA, and we are expeditiously developing our recombinant BCG candidate to address ongoing BCG shortages in the U.S. and help ensure that all eligible patients can benefit from this treatment." Richard Adcock.

Industry Context

Bladder cancer is a serious public health concern in the European Union, ranking as the fifth-most common cancer overall and seventh most frequently diagnosed in men. Approximately 200,000 patients are expected to be diagnosed with bladder cancer in 2025, with 75% (150,000) having NMIBC. There are currently no authorized treatments for BCG-unresponsive NMIBC in Europe, making ANKTIVA a significant advancement in addressing this unmet medical need.

Comparison to Industry Standards

• ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) to receive a positive recommendation for marketing authorization in Europe.
• For patients whose disease does not respond to BCG, there are currently no authorized treatment options in Europe; the primary option is surgical removal of the bladder.
• Unlike the U.S., where only one BCG substrain is approved, Europe recognizes and has approved approximately six major BCG substrains, potentially facilitating broader use of ANKTIVA.

Stakeholder Impact

• Shareholders: Positive impact due to significant regulatory milestone, potential for market expansion into Europe, and addressing an unmet medical need.
• Patients (Europe): Highly positive impact as ANKTIVA offers a new, potentially life-saving treatment option for BCG-unresponsive NMIBC, potentially avoiding radical cystectomy.
• Employees: Positive impact from company growth and successful product development.
• Healthcare Providers: Provides a new treatment tool for a challenging patient population.

Next Steps

• The EMA's opinion will be forwarded to the European Commission for final EU-wide marketing authorization.
• ImmunityBio will finalize plans to bring ANKTIVA to qualified EU patients.
• ImmunityBio will continue to follow up with trial participants and submit long-term safety and efficacy post-marketing results to the EMA.
• ImmunityBio is expeditiously developing its recombinant BCG candidate to address ongoing BCG shortages in the U.S.

Key Dates

Recommendation

The EMA's conditional marketing authorization recommendation for ANKTIVA in Europe is a pivotal regulatory achievement, opening a substantial new market for a product that addresses a critical unmet medical need in BCG-unresponsive NMIBC. The strong clinical data (71% complete response rate) and the "first-in-class" status in Europe position ImmunityBio for significant revenue growth and market penetration. While the authorization is conditional and requires post-marketing data, and the European launch strategy is being assessed, the overall impact is overwhelmingly positive, suggesting strong future prospects for the company's valuation.

Keywords

ImmunityBio, IBRX, ANKTIVA, nogapendekin alfa inbakicept, BCG, European Medicines Agency, EMA, conditional marketing authorization, non-muscle invasive bladder cancer, NMIBC, carcinoma in situ, CIS, immunotherapy, bladder cancer, oncology, biotechnology, regulatory approval, Europe, EU